The Discovery & Development of Next-Generation Long-Lasting Anti-Exhaustion TIL Therapies
Time: 2:00 pm
day: Conference Day Two - Track A - PM
Details:
- Design and development of function and persistence enhanced GT2 series TIL products engineered by StaViral® virus platform
- Development of GT3 series TIL products by CRISPR KO of potent immunoregulatory targets identified through ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform
- Preliminary safety and efficacy of next-gen TIL products in human trial as monotherapy in advanced solid tumors
